EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 32 / No 11 (Novembre 2016) Med Sci (Paris), 32 11 (2016) 968-973 References
Free Access
Issue
Med Sci (Paris)
Volume 32, Number 11, Novembre 2016
Le microbiote : cet inconnu qui réside en nous
Page(s) 968 - 973
Section Le microbiote : cet inconnu qui réside en nous
DOI https://doi.org/10.1051/medsci/20163211012
Published online 23 December 2016
  1. Nitzan O, Elias M, Peretz A. et al. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol 2016 ; 22 : 1078–1087. [CrossRef] [PubMed] [Google Scholar]
  2. Dutta AK, Chacko A. Influence of environmental factors on the onset and course of inflammatory bowel disease. World J Gastroenterol 2016 ; 22 : 1088–1100. [CrossRef] [PubMed] [Google Scholar]
  3. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol 2010 ; 6 : 339–346. [Google Scholar]
  4. Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol 2015 ; 12 : 205–217. [CrossRef] [PubMed] [Google Scholar]
  5. Sartor RB, Mazmanian SK. Intestinal microbes in inflammatory bowel diseases. Am J Gastroenterol 2012 ; 1 (suppl) : 15–21. [CrossRef] [Google Scholar]
  6. Morgan XC, Tickle TL, Sokol H. et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 2012 ; 13 : 1–18. [CrossRef] [Google Scholar]
  7. Comito D, Cascio A, Romano C. Microbiota biodiversity in inflammatory bowel disease. Ital J Pediatr 2014 ; 40 : 1–6. [CrossRef] [PubMed] [Google Scholar]
  8. Leone V, Chang EB, Devkota S. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. J Gastroenterol 2013 ; 48 : 315–321. [CrossRef] [PubMed] [Google Scholar]
  9. Serban DE. Microbiota in inflammatory bowel disease pathogenesis and therapy: is it all about diet?. Nutr Clin Pract 2015 ; 30 : 760–779. [CrossRef] [PubMed] [Google Scholar]
  10. Neuman MG, Nanau RM. Inflammatory bowel disease: role of diet, microbiota, life style. Transl Res 2012 ; 160 : 29–44. [CrossRef] [Google Scholar]
  11. Dalal SR, Chang EB. The microbial basis of inflammatory bowel diseases. J Clin Invest 2014 ; 124 : 4190–4196. [CrossRef] [PubMed] [Google Scholar]
  12. Jess T, Simonsen J, Nielsen NM. et al. Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. Gut 2011 ; 60 : 318–324. [CrossRef] [PubMed] [Google Scholar]
  13. Rodríguez LAG, Ruigómez A, Panés J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 2006 ; 130 : 1588–1594. [CrossRef] [PubMed] [Google Scholar]
  14. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012 ; 380 : 1590–1605. [CrossRef] [PubMed] [Google Scholar]
  15. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of crohn’s disease and ulcerative colitis. Am J Gastroenterol 2011 ; 106 : 2133–2142. [CrossRef] [Google Scholar]
  16. Standaert-Vitse A, Sendid B, Joossens M. et al. Candida albicans colonization and ASCA in familial Crohn’s disease. Am J Gastroenterol 2009 ; 104 : 1745–1753. [CrossRef] [PubMed] [Google Scholar]
  17. Standaert-Vitse A, Jouault T, Vandewalle P. et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of crohn’s disease. Gastroenterology 2006 ; 130 : 1764–1775. [CrossRef] [PubMed] [Google Scholar]
  18. Schuppler M, Loessner MJ. The opportunistic pathogen Listeria monocytogenes: pathogenicity and interaction with the mucosal immune system. Int J Inflam 2010 ; 2010 : 1–12. [CrossRef] [Google Scholar]
  19. Tamboli CP, Neut C, Desreumaux P. et al. Dysbiosis in inflammatory bowel disease. Gut 2004 ; 53 : 1–4. [Google Scholar]
  20. Drouet M, Vignal C, Singer E. et al. AIEC colonization and pathogenicity: influence of previous antibiotic treatment and preexisting inflammation. Inflamm Bowel Dis 2012 ; 18 : 1923–1931. [CrossRef] [PubMed] [Google Scholar]
  21. Sears CL. Enterotoxigenic Bacteroides fragilis: a rogue among symbiotes. Clin Microbiol Rev 2009 ; 22 : 349–369. [CrossRef] [PubMed] [Google Scholar]
  22. Small CL, Reid-Yu SA, McPhee JB. et al. Persistent infection with Crohn’s disease-associated adherent-invasive Escherichia coli leads to chronic inflammation and intestinal fibrosis. Nat Common 2013 ; 4 : 1–19. [Google Scholar]
  23. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011 ; 140 : 1720–1728. [CrossRef] [PubMed] [Google Scholar]
  24. Torres J, Burisch J, Riddle M. et al. Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut 2016 ; 65 : 1061–1069. [CrossRef] [PubMed] [Google Scholar]
  25. Burcelin R, Nicolas S, Blasco-Baque V. Microbiotes et maladies métaboliques : de nouveaux concepts pour de nouvelles stratégies thérapeutiques. Med Sci (Paris) 2016 ; 32 : 952–960. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  26. Gaboriau-Routhiau V, Cerf-Bensussan N. Microbiote intestinal et développement du système immunitaire. Med Sci (Paris) 2016 ; 32 : 961–967. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  27. Stetdman A, Nigro G, Sansonetti P. Le dialogue microbiote-cellules souches : un élément clé pour la régénération intestinale. Med Sci (Paris) 2016 ; 32 : 983–990. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  28. Sendid B, Jouault T, Vitse A. Glycannes pariétaux de levures et anticorps spécifiques. Med Sci (Paris) 2009 ; 25 : 473–482. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.